Through the deal, InVivo is looking to combine its neuro-spinal scaffold technology with Q Therapeutics’ adult neural progenitor cells, Cambridge, Mass.-based InVivo said. Both companies will share their technologies and explore the potential combination’s safety and feasibility for applications in the central nervous system.
“We are excited about our research collaboration with Q Therapeutics, a leading developer of adult neural progenitor cell therapies to treat debilitating CNS disease and injury. Although InVivo remains very focused on and optimistic about the potential clinical benefit of the neuro-spinal scaffold as a stand-alone technology, we believe this scientific partnership will allow both parties the opportunity to evaluate in parallel whether there is also a potential additive preclinical benefit of the combined technologies,” prez & CEO Dr. Richard Toselli said in a press release.
In August, InVivo released 12-month results from the closed Inspire study of its neuro-spinal scaffold, touting improvements in ASIA impairment scales.